Nautilus Biotechnology is trading at $2.31, down 5.53%; available reports do not identify a specific catalyst for the decline.
- Third-quarter loss was $0.12 per share, versus an expected $0.14 loss; revenue was $230,000, slightly above estimates.
- The company reported $15.6 million in net losses and $114.3 million in cash.
- It reaffirmed mid-2027 instrument availability. No source directly attributed the October 27 drop to a catalyst, and major indexes were mixed.